ArticleChemistry & biology2011
Glycolipids that elicit IFN-γ-biased responses from natural killer T cells.
Article in Chemistry & biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 43 citations in OpenAlex.
- All-Hydrocarbon Macrocycle Enables Highly Potent Th1-Biased NKT Cell Agonists for Immunotherapy.JACS Au · 2026Article
- Beyond α-GalCer: Medicinal Chemistry Insights Driving Structural Evolution of CD1d Ligands.Journal of medicinal chemistry · 2026Review
- Human NKT10 cells are enriched in cord-derived invariant natural killer T cells and mediate immune-regulation in a xenogeneic graft-versus-host disease model.Frontiers in immunology · 2026Article
- Review
- Can invariant Natural Killer T cells drive B cell fate? a look at the humoral response.Frontiers in immunology · 2025Review
- State of play in the molecular presentation and recognition of anti-tumor lipid-based analogues.Frontiers in immunology · 2024Review
- Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies.Frontiers in immunology · 2024Review
- Conformationally Restricted Analogues of α-Galactosylceramide as Adjuvant in COVID-19 Subunit Vaccine.ACS medicinal chemistry letters · 2023Article
- An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo.Nature communications · 2023Article
- Article
- α-Glucuronosyl and α-glucosyl diacylglycerides, natural killer T cell-activating lipids from bacteria and fungi.Chemical science · 2020Article
- Synthesis and biological activities of C-glycosides of KRN 7000 with novel ceramide residues.Carbohydrate research · 2017Article
- Eliciting Epitope-Specific CD8+ T Cell Response by Immunization with Microbial Protein Antigens Formulated with α-Galactosylceramide: Theory, Practice, and Protocols.Methods in molecular biology (Clifton, N.J.) · 2017Article
- Non-glycosidic compounds can stimulate both human and mouse iNKT cells.European journal of immunology · 2016Article
- Design, Synthesis, and Immunological Evaluation of Benzyloxyalkyl-Substituted 1,2,3-Triazolyl α-GalCer Analogues.ACS medicinal chemistry letters · 2016Article
- Antigen specificity of invariant natural killer T-cells.Biomedical journal · 2015Review
- Selective Conditions Are Required for the Induction of Invariant NKT Cell Hyporesponsiveness by Antigenic Stimulation.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- A Novel Glycolipid Antigen for NKT Cells That Preferentially Induces IFN-γ Production.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Review
- Lipid and Carbohydrate Modifications of α-Galactosylceramide Differently Influence Mouse and Human Type I Natural Killer T Cell Activation.The Journal of biological chemistry · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
Natural killer T (NKT) cells recognize glycolipids presented by CD1d. The first antigen described, α-galactosyl ceramide (αGalCer), is a potential anticancer agent whose activity depends upon IFN-γ secretion. We report two analogs of αGalCer based on a naturally occurring glycosphingolipid, plakoside A. These compounds induce enhanced IFN-γ that correlates with detergent-resistant binding to CD1d and an increased stability of the lipid-CD1d complexes on antigen-presenting cells. Structural analysis on one of the analogs indicates that it is more deeply bound inside the CD1d groove, suggesting tighter lipid-CD1d interactions. To our knowledge, this is the first example in which structural information provides an explanation for the increased lipid-CD1d stability, likely responsible for the Th1 bias. We provide insights into the mechanism of IFN-γ-inducing compounds, and because our compounds activate human NKT cells, they could have therapeutic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.